The aim is to assess the effectiveness of eptinezumab combined with patient education compared to placebo in reducing monthly migraine days.
Conducted a clinical trial comparing eptinezumab with patient education against a placebo with patient education.
Targeted adults suffering from chronic migraine and medication-overuse headache.
Measured the reduction of monthly migraine days (MMDs) as the primary outcome.
Eptinezumab with patient education significantly reduced monthly migraine days compared to placebo.
Class I evidence was established supporting the use of eptinezumab for this condition.
Abstract
This clinical trial provides Class I evidence that eptinezumab with patient education is superior to placebo with patient education in reducing MMDs in adults with CM and MOH.